Physician profile
Eric P Baron
NPI 1376719765
$297,290.79
in general payments reported to CMS, 2019-2025
16 companies · $46K in 2025
The $46K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $680 · 2020: $8,298 · 2021: $90K · 2022: $89K · 2023: $42K · 2024: $21K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Honoraria: $37K · Consulting Fee: $23K · Food and Beverage: $4,726 · Travel and Lodging: $1,782 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,962.50 |
| Honoraria | $36,826.00 |
| Consulting Fee | $22,516.21 |
| Food and Beverage | $4,726.46 |
| Travel and Lodging | $1,782.30 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $83,335.80 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Biohaven Pharmaceuticals, INC. | $61,585.75 | 2020-2021 | |
| Lundbeck LLC | $54,409.19 | 2021-2025 | Vyepti |
| Impel Pharmaceuticals INC. | $38,690.79 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company LTD. | $29,747.92 | 2022 | |
| Axsome Therapeutics, INC. | $11,558.21 | 2025 | Symbravo |
| Allergan, INC. | $8,754.71 | 2019-2021 | |
| Pfizer INC. | $8,062.49 | 2023-2025 | |
| Tonix Medicines, INC. | $366.25 | 2023-2025 | Zembrace Symtouch |
| Amgen INC. | $276.83 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $209.06 | 2019-2023 | Ajovy |
| Impel Pharmaceuticals LLC | $150.96 | 2024 | Trudhesa |
| Lilly USA, LLC | $92.11 | 2019 | |
| Almatica Pharma LLC | $24.16 | 2021 | |
| Siemens Medical Solutions USA, INC. | $13.38 | 2023 | Cios Flow |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Baron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.